S&P Futures
4,207.00-6.75(-0.16%)Dow Futures
33,722.00-39.00(-0.12%)Nasdaq Futures
14,084.25-45.75(-0.32%)
BioMarin Pharmaceutical Inc. (BMRN)
Chart Events
Performance Outlook
| Previous Close | 81.90 |
| Open | 82.06 |
| Bid | 78.35 x 800 |
| Ask | 82.89 x 1400 |
| Day's Range | 80.43 - 82.59 |
| 52 Week Range | 71.35 - 131.95 |
| Volume | 1,098,025 |
| Avg. Volume | 882,631 |
| Market Cap | 14.758B |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | 19.24 |
| EPS (TTM) | 4.20 |
| Earnings Date | Aug 02, 2021 - Aug 06, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.00 |
- Insider Monkey
Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]
- PR Newswire
BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on June 16, 2021 at 3:30pm ET. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
- Insider Monkey
Here’s Why ClearBridge Sold its BioMarin Pharmaceutical (BMRN) Position
ClearBridge Investments, an investment management firm, published its “SMID Cap Growth Strategy” first quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge SMID Cap Growth Strategy outperformed in the first quarter as their preference for sturdy fundamentals and value-creating management teams provided ballast amid rising speculation in newly public […]
